(R)-1-苯甲基-N-BOC-DL-脯氨酸 | 706806-60-2

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 脯氨酸类衍生物
• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 中文名称: (R)-1-苯甲基-N-BOC-DL-脯氨酸
• 中文别名: (R)-2-苄基-1-boc-2-吡咯烷羧酸
• 英文名称: (R)-2-benzyl-1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylic acid
• 英文别名: (R)-2-benzyl-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester；Boc-(R)-alpha-benzyl-proline；(2R)-2-benzyl-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid
• CAS: 706806-60-2
• 化学式: C₁₇H₂₃NO₄
• 分子量: 305.374
• InChiKey: JUUNPRGYFCIXSM-QGZVFWFLSA-N

物化性质

• 熔点：
  154-156℃

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xn
• 危险类别码：
  R22
• WGK Germany：
  3
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险性描述：
  H302,H315,H319,H332,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Boc-(R)-alpha-benzyl-proline
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H301: Toxic if swallowed
P264: Wash thoroughly after handling
P270: Do not eat, drink or smoke when using this product
P301+P310: IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician
P321: Specific treatment (see on this label)
P405: Store locked up

---

Section 3. Composition/information on ingredients.
Ingredient name: Boc-(R)-alpha-benzyl-proline
CAS number: 706806-60-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
No data
Boiling point:
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C17H23NO4
Molecular weight: 305.4

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (R)-1-苯甲基-N-BOC-DL-脯氨酸 、 三甲基硅烷化重氮甲烷 以 四氢呋喃 、 甲醇 为溶剂， 以81%的产率得到(R)-2-benzyl-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester
  参考文献：
  名称：

  Aryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof

  摘要：

  含有吡咯烷和哌啶取代基的芳基和杂芳基酮化合物，可调节5-羟色胺、去甲肾上腺素和/或多巴胺神经传导。还提供了药物组合物、使用方法和合成这些化合物的方法。

  公开号：

  US20090318493A1
• 作为产物：
  描述：

  (2R,5R)-5-benzyl-2-trichloromethyl-1-aza-3-oxabicyclo[3.3.0]octan-4-one 在 盐酸 、 三乙胺 作用下， 以 水 、 乙腈 为溶剂， 反应 17.0h， 生成 (R)-1-苯甲基-N-BOC-DL-脯氨酸
  参考文献：
  名称：

  由氨基酸配体实现的 2-丙基氮杂芳基的钯催化对映选择性 C(sp3)-H 芳基化

  摘要：

  开发了钯 (II) 催化的无偏二级 C(sp 3 )-H 键的对映选择性芳基化。对映选择性由吡啶基或异喹啉基导向基团和氨基酸N -Boc-2-戊基脯氨酸的组合控制。使用各种 2-丙基氮杂芳基和联芳基碘化物以中等至良好的产率（高达 82%）和高对映选择性（高达 93:7 er）提供芳基化产物。该反应是氨基酸启用的对映选择性无环亚甲基 C(sp 3)–H 芳基化。此外，即使在克级反应中，反应也以高对映选择性进行，产物转化为 5,6,7,8-四氢异喹啉生物活性分子。动力学同位素效应 (KIE) 实验表明，C-H 活化是对映选择性 C(sp 3 )-H 芳基化的速率决定步骤。

  DOI：

  10.1021/acs.orglett.1c04215

文献信息

• [EN] HEPATITIS C VIRUS INHIBITORS<br/>[FR] INHIBITEURS DU VIRUS DE L'HÉPATITE C
  申请人：ENANTA PHARM INC

  公开号：WO2010099527A1

  公开（公告）日：2010-09-02

  The present invention discloses compounds or pharmaceutically acceptable salts, esters, or prodrugs thereof, which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了抑制RNA含病毒，特别是丙型肝炎病毒（HCV）的化合物或药用可接受的盐、酯或前药，因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且也可用作抗病毒剂。本发明还涉及包含上述化合物的药物组合物，用于治疗患有HCV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
• NOVEL BENZIMIDAZOLE DERIVATIVES
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US20200002314A1

  公开（公告）日：2020-01-02

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了式(I)的化合物，或其药学上可接受的盐、酯或前药： 这些化合物抑制含RNA的病毒，特别是丙型肝炎病毒（HCV）。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且也可用作抗病毒剂。本发明还涉及包括上述化合物的药物组合物，用于治疗患有HCV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
• Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof
  申请人：Iyer Pravin

  公开号：US20080146607A1

  公开（公告）日：2008-06-19

  Compounds of the formula: or pharmaceutically acceptable salts thereof, wherein m, n, Ar, R 1 , R 2 , R a and R b are defined herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the compounds.

  该式化合物：或其药用可接受的盐，其中m、n、Ar、R1、R2、Ra和Rb在此处有定义。还提供了制药组合物、使用方法和制备该化合物的方法。
• [EN] NOVEL BENZIMIDAZOLE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS DE BENZIMIDAZOLE
  申请人：ENANTA PHARM INC

  公开号：WO2013052369A1

  公开（公告）日：2013-04-11

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明揭示了式（I）的化合物，或其药学上可接受的盐、酯或前药：其抑制RNA含量的病毒，特别是丙型肝炎病毒（HCV）。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及包含上述化合物的制药组合物，用于治疗患有HCV感染的受试者。本发明还涉及通过给受试者注射包含本发明化合物的制药组合物来治疗HCV感染的方法。
• Pyrrolidinyl and piperidinyl ketone derivatives and uses thereof
  申请人：Roche Palo Alto LLC

  公开号：US08084623B2

  公开（公告）日：2011-12-27

  Compounds of the formula: or pharmaceutically acceptable salts thereof, wherein m, n, Ar, R1, R2, Ra and Rb are defined herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the compounds.

  本发明提供了化合物的公式：或其药学上可接受的盐，其中m，n，Ar，R1，R2，Ra和Rb在此定义。还提供了制药组合物、使用方法和化合物的制备方法。